Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | UGCG | Q16739 | 2/20 | 0.39 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29606950 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL2186406 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL2186409 | 1.00 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL334897 | 0.89 | MEN1 (0.64) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL15516358 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL334794 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL12903278 | 0.88 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1PDE4D | |
| SCHEMBL31549217 | 0.86 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1TDP1 | |
| SCHEMBL8478562 | 0.86 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1TDP1 | |
| SCHEMBL14250237 | 0.86 | MEN1 (0.55) | MEN1KMT2ATSHRTAAR1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-24 | — | — | US | disclosed |
| CN-112437768-B | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-4242204-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-4242204-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-09-13 | — | — | EP | disclosed |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2022-09-29 | — | — | US | disclosed |
| EP-1042302-B1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING & MFG (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6309561-B1 | Liquid crystal compounds having a chiral fluorinated terminal portion | 3M INNOVATIVE PROPERTIES COMPANY | 2001-10-30 | — | — | US | disclosed |
| EP-1135450-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6139924-A | CONTAINING A PYRIMIDINE RING | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| EP-1042302-A1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000031210-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-1999033814-A1 | LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5530143-A | REDUCTION OF (3S)-3-HYDROXYOCTANEDIOIC DIESTER WITH COMPLEX HYDRIDE | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0487986-B1 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF AG (DE) | 1995-06-21 | — | — | EP | disclosed |
| EP-0487986-A2 | Process for the preparation of esters of (6s)-6,8-dihydroxyoctanoic acid | BASF Aktiengesellschaft (DE) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR1B, HTR7, HTR6 | MEN1 3743/4885KMT2A 3250/4885TSHR 92/4885 |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | ENTPD5, ENTPD1, NT5E | MEN1 2174/4885KMT2A 2995/4885TSHR 2133/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | MEN1 2505/4885KMT2A 2348/4885TSHR 91/4885 |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, TPH2 | MEN1 3067/4885KMT2A 1855/4885TSHR 170/4885 |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR1A | MEN1 2359/4885KMT2A 3467/4885TSHR 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.